PRAXNasdaqPharmaceutical PreparationsUS GAAP · USD

Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. is a U.S.-based biopharmaceutical company focused on developing therapies for central nervous system disorders. Its pipeline includes product candidates for epilepsy, essential tremor, and other neurological diseases, with development conducted through a virtual model that relies on external research, clinical, and manufacturing partners.

Kysy yhtiöstä
Liikevaihto0,0milj. USD
−100,0 %v/v
Liikevoitto (EBIT)−326milj. USD
−63,0 %v/v
Nettotulos−303milj. USD
−65,9 %v/v
Vapaa kassavirta−249milj. USD
−89,1 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−400−300−200−1000100milj. USD2020: EBIT −62 milj. USD20202021: EBIT −167 milj. USD20212022: 0,00 milj. USD2022: EBIT −215 milj. USD20222023: 2,4 milj. USD2023: EBIT −126 milj. USD20232024: 8,6 milj. USD2024: EBIT −200 milj. USD20242025: 0,00 milj. USD2025: EBIT −326 milj. USD20250,00−326
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Neurology drug candidates70 %

Clinical-stage therapies targeting movement disorders and epilepsy-related CNS conditions.

Preclinical pipeline20 %

Earlier-stage antisense programs aimed at genetically defined neurological disorders.

Collaboration revenue10 %

Research and development collaboration income from partnered programs.

Asiakkaat

Praxis does not yet sell commercial products; its near-term counterparties are regulators, clinical investigators, contract research organizations, and contract manufacturers that support development. If approved, its customers would be physicians, hospitals, specialty neurology practices, and third-party payors that determine access and reimbursement for patients with neurological disorders.

Neurology prescribers

Specialists who would prescribe ulixacaltamide, relutrigine, or vormatrigine if approved, based on efficacy and safety in difficult-to-treat CNS disorders.

Third-party payors

Commercial insurers and government programs that would determine coverage and reimbursement for approved therapies.

Clinical development partners

CROs, CDMOs, and consultants that provide trial execution, manufacturing, and regulatory support.

Patients with rare or refractory neurological disease

Patients with essential tremor, epilepsy, or genetically defined neurodevelopmental disorders who are the end beneficiaries of the pipeline.

Strategia

Praxis is advancing a pipeline of precision medicines for neurological disease, with emphasis on late-stage clinical programs and regulatory submissions. It is also building the commercial infrastructure, manufacturing network, and intellectual property base needed to support potential launches and future partnering.

Advance late-stage neurology programsLyhyt aikaväli

Clinical and regulatory progress is the main path to future product revenue.

Build commercialization readinessLyhyt aikaväli

Approved products will require sales, marketing, distribution, and payer access capabilities.

Expand the precision neurology pipelineKeskipitkä aikaväli

A broader pipeline can diversify scientific risk and create follow-on value.

Maintain IP and external development modelPitkä aikaväli

The company depends on proprietary science and outsourced execution to scale efficiently.

Maantiede

Praxis is headquartered in the United States and conducts most of its development and corporate activity from there. Its commercial opportunity is primarily U.S.-focused initially, while future approval and reimbursement would also depend on foreign regulatory and pricing systems, especially in Europe.

Riskit

Praxis faces the core risks of a clinical-stage biopharmaceutical company: clinical failure, regulatory setbacks, and uncertainty around eventual market adoption. Because it relies on third parties for manufacturing and development, execution risk, supply continuity, and reimbursement access are also material to the business model.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Clinical development failure1Regulatory approval risk2Manufacturing and supply chain dependence3Commercial adoption and reimbursement4Capital needs5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Clinical development failureVaikutus: KriittinenTodennäköisyys: Korkea

    The company has no approved products and depends on successful trial outcomes to create value.

    KohdistuuUlixacaltamideRelutrigineVormatrigineElsunersen
  2. Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Even positive data may not translate into FDA approval or a timely review process.

    Kohdistuu: NDA and registrational-stage programs

  3. Manufacturing and supply chain dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen

    All clinical and future commercial supply is outsourced to third-party CDMOs.

    KohdistuuDrug substanceFill-finishPackagingDistribution
  4. Commercial adoption and reimbursementVaikutus: KorkeaTodennäköisyys: Matala

    Prescribers and payors may be slow to adopt new CNS therapies, especially for unfamiliar mechanisms.

    Kohdistuu: Essential tremor and epilepsy markets

  5. Capital needsVaikutus: KorkeaTodennäköisyys: Matala

    The company expects to fund operations through external capital until product sales exist, if ever.

    KohdistuuR&DTrialsCommercialization buildout

Kirjanpito

Harkinnanvaraiset erät
Research and development accruals

Clinical and preclinical work is outsourced, so expenses must be estimated before invoices are final.

Vaikutus: Can materially affect quarterly operating expense and liabilities

Collaboration revenue recognition

Revenue from the UCB collaboration depends on the timing of service obligations and option exercise.

Vaikutus: Can create uneven non-product revenue

Vendor termination obligations

Certain clinical vendors cannot be terminated without reimbursing unrecoverable outlays.

Vaikutus: Creates contingent commitments and cash flow risk

IP and licensing arrangements

In-licenses and collaborations may involve upfront payments, milestones, or contingent consideration.

Vaikutus: Affects expense timing and future obligations

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Precision BioSciences, Inc

DTIL · Biological Products, (No Diagnostic Substances)

Rapport Therapeutics, Inc.

RAPP · Pharmaceutical Preparations

Precigen, Inc

PGEN · Pharmaceutical Preparations

Revolution Medicines, Inc.

RVMD · Biological Products, (No Diagnostic Substances)

Pasithea Therapeutics Corp.

KTTA · Pharmaceutical Preparations

ProMIS Neurosciences Inc.

PMN · Pharmaceutical Preparations

Päivitetty: 24.9.2026